Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...

CEO Jim Frakes noted that Aethlon Medical has made significant progress in focusing on oncology and implementing cost reductions. Operating expenses were reduced by 50% compared to the same quarter ...

Anixa Biosciences (ANIX) announced that it, along with its partner Moffitt Cancer Center, has received approval for an amendment to the ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt ...

along with its partner Moffitt Cancer Center ("Moffitt"), has received approval for an amendment to the protocol governing its ongoing clinical trial using CAR-T therapy for the treatment of ...

In this video interview, Dominique Demolle, CEO of Cognivia, highlights how patient non-adherence could increase trial ...

The new Phase 2 clinical trial protocol focuses on a specific patient population (advanced, recurrent, platinum-resistant ovarian cancer patients) with limited treatment options, highlighting the ...

To avoid a tug-of-war between scientific rigour and operational efficiency, we must focus on the user and data journeys of ...

AEMD READ THE FULL AEMD RESEARCH REPORT Patient treatments begin in AEMD’s basket oncology trial, enrollments expected to accelerate Aethlon Medical (NASDAQ:AEMD) reported FY 3Q results yesterday and ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed ...

A major shift in stroke care is underway as tenecteplase outperforms alteplase. This new treatment could redefine recovery ...